ClinicalTrials.gg
RecruitingNCT07092007Updated Jul 29, 2025

NWRD09 for HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer

An interventional study of NWRD09 administered by intramuscular injection in Intraepithelial Neoplasia and Cervical Cancer, sponsored by Newish Technology (Beijing) Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Newish Technology (Beijing) Co., Ltd. (part of Newish Biotech (Wuxi) Co., Ltd.) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Jun 2024, registered Jul 2025).
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

This is a single-arm, open label, two cohorts, multi-center clinical study to evaluate the safety and efficacy of HPV-16 targeted mRNA vaccine (NWRD09) in HPV-16 related Cervical, vaginal, and vulvar intraepithelial neoplasia (LSIL and HSIL) patients (cohort A) and HPV-16 related cervical cancer patients (cohort B).

Read the detailed description

This study is divided into three dose groups in two cohorts. Each patient will be administered NWRD09 by intramuscular injection. The Maximum Tolerated Dose of NWRD09 will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.

For cohort A, the subjects shall continue to receive safety follow-up until 14 days after the last administration. Colposcopy and biopsy were performed at week 24.

For cohort B, the subjects shall continue to receive safety follow-up until 14 days after the last administration. Imaging evaluation was performed every 6 weeks.

02

Conditions studied

  • Intraepithelial Neoplasia
  • Cervical Cancer

Keywords

  • HPV16
  • Intraepithelial Neoplasia
  • Cervical Cancer
  • mRNA vaccine
03

In context

Carcinoma in Situ

78 studies on the registry are indexed under Carcinoma in Situ; 22 are open to participants now.

This study's planned enrollment of 18 is below the median of 80 across 62 interventional studies indexed under Carcinoma in Situ.

Browse Carcinoma in Situ studies →

Lead sponsor

Newish Technology (Beijing) Co., Ltd. is the lead sponsor of 8 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion criteria for cohort A:

Patients had to meet all of the following inclusion criteria:

  1. Women aged between 18 and 60 years.
  2. HPV16 is positive during the screening period.
  3. confirmed HPV-16-associated cervical, vaginal, and vulvar intraepithelial neoplasia (LSIL and HSIL). In the case of LSIL, it is necessary to meet persistent HPV16 infection for more than 6 months. In the case of HSIL, it is necessary to meet the requirements of satisfactory colposcopy at screening, which is defined as the squamous columnar epithelial junction (class I or class II transformation zone) is fully visible, and the upper limit of the white epithelium acetate or suspected CIN lesions are fully visible.
  4. Eligible subjects of must agree to use a reliable method of (hormonal or barrier method or abstinence, etc.) with their partner for the duration of the trial or for at least 6 months after the last dose. For premenopausal women with the possibility of childbearing, blood pregnancy tests must be negative within 7 days prior to the first use of the NWRD09.
  5. Have fully understood the study and voluntarily signed the ICF, have good communication with the investigator, and are able to complete all treatments, examinations, and visits stipulated in the study protocol.

Inclusion criteria for cohort B:

Patients had to meet all of the following inclusion criteria:

  1. Women aged ≥ 18 years.
  2. HPV16-related recurrent or advanced cervical cancer (Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma) patients who have progressed after at least one lines of standard therapy or are intolerant to toxic side effects, or for which there is no standard treatment at present (Treatment failure refers to: disease progression during or after treatment with systemic antineoplastic regimens; Intolerance refers to: the patient has grade 3-4 adverse reactions after receiving standard therapy, and the patient refuses to continue the original treatment).
  3. At least 1 ( 1.1). Tumor lesions that have received prior radiotherapy or other local therapy are considered measurable only if disease progression at the treatment site is clearly documented after completion of treatment.
  4. (ECOG) Performance status of 0 or 1.
  5. Had recovered from all toxicities related to prior anticancer therapies to grade≤1 or baseline level as defined by v5.0 (except for the asymptomatic laboratory examination abnormalities such as elevated ALP, hyperuricemia, elevated serum amylase/lipase, elevated blood glucose, etc., and toxicities judged by the investigator to have no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, and hypothyroidism stabilized by hormone replacement therapy, etc.).
  6. Major organ functions must meet the following criteria:

    1. Blood routine: (ANC) ≥ 1.5×10\^9/L, count ≥ 80×10\^9/L, ≥ 90 g/L,
    2. Liver function: total (TBIL) ≤ 1.5 (≤ 3 ULN for Gilbert's syndrome, liver cancer, or liver metastases), and ALT ≤ 2.5 ULN for subjects without liver metastases, and ≤ 5.0 ULN for subjects with liver metastases,
    3. Renal function: creatinine (Cr) ≤ 1.5 ULN, or (Ccr) ≥ 50 mL/min (using the Cockcroft and Gault formula),
    4. Coagulation function: (INR) ≤ 1.5, and activated partial thromboplastin time (APTT) ≤ 1.5 ULN.
  7. Has of at least 3 months in the best judgement of the investigator.
  8. Eligible subjects of childbearing potential must agree to use a reliable method of contraception (hormonal or barrier method or abstinence, etc.) with their partner for the duration of the trial or for at least 6 months after the last dose. For premenopausal women with the possibility of childbearing, blood pregnancy tests must be negative within 7 days prior to the first use of the NWRD09.
  9. Have fully understood the study and voluntarily signed the ICF, have good communication with the investigator, and are able to complete all treatments, examinations, and visits stipulated in the study protocol.

Exclusion Criteria:

Exclusion criteria for cohort A:

Patients with any of the following were excluded from the study:

  1. Any histopathologically confirmed adenocarcinoma or adenocarcinoma in situ (AIS) or invasive cancer.
  2. Pregnant, breastfeeding, or planning to conceive during the study period.
  3. Received any non- injection within 2 weeks prior to the first dose of NWRD09.
  4. Received any live vaccine injection within 4 weeks prior to the first dose of NWRD09.
  5. Received treatment for LSIL or HSIL within 4 weeks prior to the first dose of NWRD09.
  6. Participated in another clinical trial or is in the observation period of another clinical trial within 30 days prior to screening.
  7. Continuous (more than 1 week) use of (equivalent to >10 mg/day of prednisone) within 30 days prior to screening, except for hormone replacement therapy and local administration such as inhaled or ocular treatments.
  8. History of immunodeficiency or diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis).
  9. Current or anticipated use of disease-modifying antirheumatic drugs (e.g., azathioprine, cyclophosphamide, cyclosporine, methotrexate) and biological agents (e.g., infliximab, adalimumab, etanercept).
  10. Continuous (more than 1 week) use of (e.g., cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, and anti-lymphocyte globulin) within 30 days prior to screening.
  11. History of solid organ or bone marrow transplantation.
  12. Past or current , except for adequately treated and completely cured ductal carcinoma in situ of the breast, basal cell carcinoma of the skin, superficial bladder tumors, or any other malignancies cured more than 5 years before entering the study.
  13. Uncontrolled severe infections (>Grade 2 NCI-CTCAE adverse events, version 5.0).
  14. History of infection or syphilis carrier.
  15. Active infection (e.g., acute bacterial infection, tuberculosis, active syphilis, active phase of herpes zoster virus infection, active or C, etc.).

    ① Active is defined as: positive hepatitis C antibody and HCV-RNA positive.

    ② Active HIV infection is defined as: positive HIV antibody.

    ③ Active hepatitis B is defined as: HBV titer ≥ 2000 IU/mL (except for subjects who have received anti-HBV treatment for at least 14 days before the first dose and agree to continue antiviral therapy during the study period).

  16. Severe allergy history, or history of atopic diseases, or an allergic constitution, if any of these are met.
  17. History of severe or multiple to drugs or pharmaceutical preparations.
  18. History of severe local or systemic reaction to vaccines, defined as:

    1. Local reaction: extensive, indurated redness and swelling involving most of the arm, unresolved within 72 hours.
    2. Systemic reaction: persistent fever ≥ 39.5°C within 48 hours. bronchospasm. laryngeal edema. syncope. convulsions or encephalopathy within 72 hours.
  19. Severe dysfunction of other organs or heart and lung diseases.
  20. History of definite neurological or psychiatric disorders, including epilepsy or dementia.
  21. History of drug abuse or alcoholism.
  22. Pregnant or breastfeeding women, or women of childbearing age with a positive blood pregnancy test, or patients and their partners of childbearing potential unwilling to use effective contraception during the clinical study and for 6 months after the end of treatment.
  23. Patients deemed unsuitable to participate in this clinical trial by the investigator.

Exclusion criteria for cohort B:

Patients with any of the following were excluded from the study:

  1. Cervical carcinoma in situ that can be cured by local treatment or non-HPV related cervical cancer.
  2. Has not recovered or be reasonably explained from all toxicities related to prior treatments such as surgery, radiotherapy, chemotherapy, immunotherapy, etc.
  3. Participated in another clinical trial or is in the observation period of another clinical trial within 30 days prior to screening.
  4. Received any non-live vaccine injection within 2 weeks prior to the first dose.
  5. Received any live vaccine injection within 4 weeks prior to the first dose.
  6. Continuous (more than 1 week) use of corticosteroids (equivalent to >10 mg/day of prednisone) within 30 days prior to screening, except for hormone replacement therapy and local administration such as inhaled or ocular treatments.
  7. History of immunodeficiency or autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis).
  8. Current or anticipated use of disease-modifying antirheumatic drugs (e.g., azathioprine, cyclophosphamide, cyclosporine, methotrexate) and biological agents (e.g., infliximab, adalimumab, etanercept).
  9. Continuous (more than 1 week) use of immunosuppressants (e.g., cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, and anti-lymphocyte globulin) within 30 days prior to screening.
  10. History of solid organ or bone marrow transplantation.
  11. Past or current malignancies, except for adequately treated and completely cured ductal carcinoma in situ of the breast, basal cell carcinoma of the skin, superficial bladder tumors, or any other malignancies cured more than 5 years before entering the study.
  12. Central nervous system (CNS) metastases and/or carcinomatous meningitis (meningeal metastasis).
  13. or recurrent pleural, peritoneal, or pericardial effusion requiring frequent drainage.
  14. Uncontrolled severe infections (>Grade 2 NCI-CTCAE adverse events, version 5.0).
  15. History of HIV infection or syphilis carrier.
  16. Active infection (e.g., acute bacterial infection, tuberculosis, active syphilis, active phase of herpes zoster virus infection, active hepatitis B or C, etc.).

    ① Active hepatitis C is defined as: positive hepatitis C antibody and HCV-RNA positive.

    ② Active HIV infection is defined as: positive HIV antibody.

    ③ Active hepatitis B is defined as: HBV titer ≥ 2000 IU/mL (except for subjects who have received anti-HBV treatment for at least 14 days before the first dose and agree to continue antiviral therapy during the study period).

  17. Severe allergy history, or history of atopic diseases, or an allergic constitution, if any of these are met.
  18. History of severe or multiple hypersensitivity to drugs or pharmaceutical preparations.
  19. History of severe local or systemic reaction to vaccines, defined as:

    1. Local reaction: extensive, indurated redness and swelling involving most of the arm, unresolved within 72 hours.
    2. Systemic reaction: fever ≥ 39.5°C within 48 hours. bronchospasm. laryngeal edema. syncope. convulsions or encephalopathy within 72 hours.
  20. Severe dysfunction of other organs or heart and lung diseases.
  21. History of definite neurological or psychiatric disorders, including epilepsy or dementia.
  22. History of drug abuse or alcoholism.
  23. Pregnant or breastfeeding women, or women of childbearing age with a positive blood pregnancy test, or patients and their partners of childbearing potential unwilling to use effective contraception during the clinical study and for 6 months after the end of treatment.
  24. Patients deemed unsuitable to participate in this clinical trial by the investigator.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Cohort A( HPV-16 related Cervical, vaginal, and vulvar intraepithelial neoplasia patients )

    Patients will be assigned to three dose groups. Each patient will be administered NWRD09 by intramuscular injection. The Maximum Tolerated Dose of NWRD09 will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.

    Biological: NWRD09 administered by intramuscular injection

  • Experimental
    Cohort B(HPV-16 related cervical cancer patients)

    Patients will be assigned to three dose groups. Each patient will be administered NWRD09 by intramuscular injection. The Maximum Tolerated Dose of NWRD09 will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.

    Biological: NWRD09 administered by intramuscular injection

Interventions

06

What researchers measure

Primary outcomes

  1. Safety(Cohort A and B)

    All adverse events (AE) will be determined based on the rate and severity grade of events, including incidence and severity of serious adverse events (SAE) (according to NCI-CTCAE Standard version 5.0 of common Terms for Adverse Events).

    Time frame: From first administration of NWRD09 to 14 days after the last administration

  2. Dose-limiting toxicity (DLT) (Cohort A and B)

    It would be determined based on the rate and severity grade of events or abnormalities through evaluating systemic or local adverse events, clinical laboratory test results, vital signs that is definitely, probably, or possibly related to the test drug occurring within 21 days of the first dosing will be classified as DLT during dosing climb.

    Time frame: 14 days after the first administration

Secondary outcomes

  1. Immunogenicity (Cohort A and B)

    Immunologic reactogenicity by measuring HPV16 E6/E7 specific T cell response (IFN-γ ELISPOT) in blood samples.

    Time frame: To week 24.

  2. Histopathology outcome and HPV Viral clearance (Cohort A)

    Number of subjects with virologically-proven clearance of HPV 16 and number of subjects with histopathological regression of cervical lesions to CIN 1 or normal.

    Time frame: To week 24.

  3. Objective Response Rate (ORR) (Cohort B)

    bjective Response Rate (ORR), defined as the proportion of patients who have either confirmed CR or confirmed PR as best overall response per RECIST 1.1.

    Time frame: To week 24.

  4. Progression-free survival (PFS) (Cohort B)

    Progression-free survival (PFS), defined as the time from the NWRD09 treatment start date to the date of the first documented progression or death from any cause, whichever occurs first.

    Time frame: To week 24.

  5. Duration of response (DOR) (Cohort B)

    Duration of response (DOR), defined as time from the date of first documented response of CR or PR to the date of the first documented progression or death due to any cause.

    Time frame: To week 24.

  6. Disease control rate (DCR) (Cohort B)

    Disease control rate (DCR), defined as is the percentage of evaluable cases with response (PR + CR) and stable disease (SD) after treatment, DCR = CR + PR + SD.

    Time frame: To week 24.

07

Study locations

1 of 1 sites recruiting
  • Heze Municipal Hospita
    Heze, Shandong, China
    Recruiting
    • Guodong Sun, Master · Contactsunguodong0723@163.com · (+86)0530-5613206
    • Guodong Sun, Master · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Dec 2025, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Jul 29, 2025
StartActual
Jun 5, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07092007
Responsible party
Sponsor
First posted
Jul 29, 2025
Start date
Jun 5, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jul 29, 2025

Study contacts

Guodong Sun, Master
Contact
sunguodong0723@163.com
(+86)0530-5613206

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NWRD09

Start the discussion